Novelix Pharmaceuticals files SAST disclosure for acquisition of Srinidhi Fine‑Chemicals LLP

What Novelix Pharmaceuticals announced

On 13 July 2026, Novelix Pharmaceuticals Ltd filed a disclosure with the Bombay Stock Exchange under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing informs the market that the company, together with other investors, has undertaken a substantial acquisition of shares in Srinidhi Fine‑Chemicals LLP.

The announcement itself contains no further quantitative details – such as the number of shares acquired, the percentage of total equity, or the consideration paid – but it satisfies the statutory requirement to notify the exchange when a party acquires a material stake in a listed entity or a related unlisted entity.

Details of the SAST filing

Regulation 29(2) requirement

SEBI mandates that any person or entity acquiring shares that cross prescribed thresholds (typically 5 % and above) must disclose the acquisition to the stock exchange within two trading days. The disclosure must include the identity of the acquirer, the target entity, the number of shares acquired, and the percentage of voting rights held post‑acquisition.

In this case, Novelix Pharmaceuticals has complied by filing the required form, naming Srinidhi Fine‑Chemicals LLP and “Others” as the target parties. The filing does not elaborate on the exact share count or the percentage held, which suggests that the detailed schedule may be submitted separately or is pending finalisation.

Parties involved

• Acquirer: Novelix Pharmaceuticals Ltd (BSE: 536565)
• Target: Srinidhi Fine‑Chemicals LLP and other associated parties (unnamed in the filing)
• Filing date: 13 July 2026, 14:02:38 UTC

Key facts at a glance

Why this matters for investors

The filing confirms that Novelix Pharmaceuticals is expanding its strategic footprint through a share acquisition in the chemical‑manufacturing space. While the exact size of the stake is not disclosed, the requirement to file under Regulation 29(2) indicates that the acquisition is material enough to meet SEBI’s threshold. Investors should monitor subsequent disclosures for details on the percentage held, the price paid, and any related agreements, as these will clarify the financial impact on Novelix’s balance sheet and potential synergies with the target business.

Conclusion

Novelix Pharmaceuticals has complied with SEBI’s SAST reporting obligations by notifying the market of a substantial share acquisition in Srinidhi Fine‑Chemicals LLP on 13 July 2026. The filing does not provide quantitative specifics, and further information may be released in later disclosures or in the detailed schedule accompanying the SAST filing. Investors should await those details to assess the full implications of the transaction.